RxDoctor Payments Data

Vikram Rao, MD

Neurology · San Francisco, CANPI 1316106859

Payments from drug & device makers

$138,563in general payments, 2019–2025

Across 144 payments — averaging $962.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neuropace, Inc.$103K
  • Medtronic$27K
  • Livanova USA, Inc.$8K
  • Vertex$427
  • SK Life Science, Inc.$118
  • Zimmer Biomet$57
  • plus $76 from 2 others

What the payments were for

  • Consulting fees$85,08880%
  • Speaking & faculty fees$7,7157%
  • Travel & lodging$5,9266%
  • Food & beverage$4,7124%
  • Education$2,4362%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Neuropace, Inc.119$102,618
Medtronic(3 entities)8$27,259
Livanova USA, Inc.11$8,009
Vertex1$427
SK Life Science, Inc.1$118
Zimmer Biomet1$57
Penumbra, Inc.2$40
Neurelis, Inc.1$36

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$138,563 in reported general payments places this provider in the 90th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$63,120
Medicare patients
165
Services billed
438

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AptiomEslicarbazepine Acetate23$85,521
EpidiolexCannabidiol (Cbd)13$39,475
ValtocoDiazepam21$37,081
Clobazam85$22,233
XcopriCenobamate11$20,072
VimpatLacosamide13$18,951
Lacosamide79$9,833
Levetiracetam112$8,088
Lamotrigine ErLamotrigine26$7,675
Diazepam12$4,403
DilantinPhenytoin Sodium Extended20$3,835
Oxcarbazepine48$3,691
Clorazepate Dipotassium17$3,649
Lamotrigine49$3,063
Zonisamide43$2,153

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurelis, Inc.Valtoco$36$37,08121 claims
SK Life Science, Inc.Xcopri$118$20,07211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,996 neurology providers in California.

Other neurology in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →